For all location-dependent subgroups, Table 3 lists overall survival, prevalence of preoperative or general multifocality of the tumors, absolute and relative numbers of MGMT promotor methylation status, Ki-67 proliferation index (defined as above or below 30%, or not evaluated), median and mean KPS score and prevalence of epileptic seizures at the time of initial diagnosis. This evidence concerns the gene MGMT and Seizure.